Research programme: cancer therapeutics - Coronado Biosciences

Drug Profile

Research programme: cancer therapeutics - Coronado Biosciences

Alternative Names: 8r; Apogossypol; CNDO 103

Latest Information Update: 09 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Burnham Institute
  • Developer Coronado Biosciences
  • Class
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 May 2011 Discontinued - Preclinical for Cancer in USA (PO)
  • 01 Mar 2010 Preclinical development is ongoing USA
  • 28 Jan 2008 Pharmacodynamics data from a preclinical study released by Coronado Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top